CN113795510A - 抗pd-l1抗体及其应用 - Google Patents

抗pd-l1抗体及其应用 Download PDF

Info

Publication number
CN113795510A
CN113795510A CN202080013686.1A CN202080013686A CN113795510A CN 113795510 A CN113795510 A CN 113795510A CN 202080013686 A CN202080013686 A CN 202080013686A CN 113795510 A CN113795510 A CN 113795510A
Authority
CN
China
Prior art keywords
amino acid
seq
antibody
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080013686.1A
Other languages
English (en)
Inventor
房健民
姜静
李慎军
赵国锐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rongchang Biopharmaceutical Yantai Co Ltd
Original Assignee
Rongchang Biopharmaceutical Yantai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rongchang Biopharmaceutical Yantai Co Ltd filed Critical Rongchang Biopharmaceutical Yantai Co Ltd
Publication of CN113795510A publication Critical patent/CN113795510A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

本发明提供了一种PD‑L1免疫抑制剂，具体提供了一种能够靶向PD‑L1的单克隆抗体以及编码这些抗体的核苷酸、多核苷酸组合、表达载体以及表达载体组合。本发明还提供了包含上述抗PD‑L1抗体的偶联物或者药物组合物。本发明还提供了上述抗PD‑L1抗体核苷酸、多核苷酸组合、表达载体、表达载体组合、偶联物或者药物组合物在治疗或预防癌症的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN202080013686.1A 2019-08-29 2020-08-25 抗pd-l1抗体及其应用 Pending CN113795510A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019108054407 2019-08-29
CN201910805440 2019-08-29
PCT/CN2020/110935 WO2021037007A1 (zh) 2019-08-29 2020-08-25 抗pd-l1抗体及其应用

Publications (1)

Publication Number Publication Date
CN113795510A true CN113795510A (zh) 2021-12-14

Family

ID=74684171

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080013686.1A Pending CN113795510A (zh) 2019-08-29 2020-08-25 抗pd-l1抗体及其应用

Country Status (11)

Country Link
US (1) US20220177590A1 (zh)
EP (1) EP3858862A4 (zh)
JP (1) JP2022521958A (zh)
KR (1) KR20220012856A (zh)
CN (1) CN113795510A (zh)
AU (1) AU2020339478A1 (zh)
BR (1) BR112021016512A2 (zh)
CA (1) CA3114467A1 (zh)
SG (1) SG11202103221QA (zh)
TW (1) TWI788698B (zh)
WO (1) WO2021037007A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114990129A (zh) * 2022-05-11 2022-09-02 北京贝来生物科技有限公司 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115073599B (zh) * 2021-03-16 2023-04-28 北京天广实生物技术股份有限公司 结合pd-l1的抗体及其用途
CN115814091A (zh) * 2022-12-19 2023-03-21 中山大学 Cd43抑制剂在制备抗结直肠肿瘤药物中的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005874A2 (en) * 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CN107840887A (zh) * 2016-09-21 2018-03-27 基石药业（苏州）有限公司 一种新的pd‑1单克隆抗体
JP2018536401A (ja) * 2015-11-17 2018-12-13 スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
CN109232740A (zh) * 2018-08-20 2019-01-18 中国科学院微生物研究所 一种抗pd-l1抗体及其在抗肿瘤治疗中的应用
CN109627338A (zh) * 2019-01-25 2019-04-16 苏州药明泽康生物科技有限公司 一种新型抗人pd-l1抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN109715821B (zh) * 2016-01-29 2022-09-06 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
US11660352B2 (en) * 2016-03-29 2023-05-30 Stcube, Inc. Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
JP7461741B2 (ja) * 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
EP3470429A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
TW201930350A (zh) * 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｐｄ－ｌ１之抗體及其變異體
KR20220107257A (ko) * 2020-03-20 2022-08-02 레메젠 코, 리미티드 이중특이성 융합 단백질 및 그의 응용

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005874A2 (en) * 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
JP2018536401A (ja) * 2015-11-17 2018-12-13 スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
CN107840887A (zh) * 2016-09-21 2018-03-27 基石药业（苏州）有限公司 一种新的pd‑1单克隆抗体
CN109232740A (zh) * 2018-08-20 2019-01-18 中国科学院微生物研究所 一种抗pd-l1抗体及其在抗肿瘤治疗中的应用
CN109627338A (zh) * 2019-01-25 2019-04-16 苏州药明泽康生物科技有限公司 一种新型抗人pd-l1抗体及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENJAMIN B等: "Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti - PD-LI Antibody Avelumab (MSBO010718C) on Human Tumor Cells", CANCER IMMUNOLOGYRESEARCH, vol. 3, no. 10, pages 1148 - 1157 *
秦琪;刘朝奇;熊焱强;李倩;李志英;: "PD-1/PD-L1信号通路及相关抗体在宫颈癌免疫治疗中的应用", 生命的化学, no. 06, pages 120 - 125 *
车耀健;赵宁宁;胡妍;杨丰云;温振国;: "抗EGFR/CD3双特异性抗体的制备与功能的初步研究", 福建医科大学学报, no. 06, pages 31 - 36 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114990129A (zh) * 2022-05-11 2022-09-02 北京贝来生物科技有限公司 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
CN114990129B (zh) * 2022-05-11 2023-02-03 北京贝来生物科技有限公司 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用

Also Published As

Publication number Publication date
TWI788698B (zh) 2023-01-01
TW202115121A (zh) 2021-04-16
WO2021037007A1 (zh) 2021-03-04
US20220177590A1 (en) 2022-06-09
KR20220012856A (ko) 2022-02-04
EP3858862A9 (en) 2021-10-06
SG11202103221QA (en) 2021-04-29
EP3858862A1 (en) 2021-08-04
AU2020339478A1 (en) 2021-05-06
CA3114467A1 (en) 2021-03-04
EP3858862A4 (en) 2022-07-13
JP2022521958A (ja) 2022-04-13
BR112021016512A2 (pt) 2022-03-15

Similar Documents

Publication Publication Date Title
RU2693661C2 (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
JP7464764B2 (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
CN111944050B (zh) 一种抗b7-h3抗体及其应用
JP2020504095A (ja) 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体
EP4353745A1 (en) A group of b7h3 monoclonal antibodies and medical use thereof
JP2018531219A6 (ja) Ｐｄ−ｌ１抗体
CN110407941B (zh) Cd39的高亲和力抗体及其用途
TWI788698B (zh) 抗ｐｄ-ｌ１抗體及其應用
US20200392238A1 (en) Human tnfrsf25 antibody
EP4039704A1 (en) Anti-pd-1 antibody and use thereof
JP2022505330A (ja) Ｌｒｉｇ－１タンパク質に特異的な結合分子及びその用途
CN112513088A (zh) 抗ox40抗体、其抗原结合片段及其医药用途
EP4292611A1 (en) Anti-cd112r antibody and use thereof
EP4265644A1 (en) Bispecific antibody for specifically neutralizing tgf-? signal of helper t cell, and pharmaceutical combination and use thereof
US20230257465A1 (en) ANTI-PDL1 x EGFR BISPECIFIC ANTIBODY
CN114478768A (zh) 抗cd73的抗体及其用途
RU2783685C2 (ru) Анти-pd-l1 антитело и его применение
US20230151090A1 (en) Composition comprising an ige antibody
US20240084026A1 (en) Anti-4-1bb antibodies and methods of making and using thereof
EP4049675A1 (en) Combination of anti-garp antibody and immunoregulator

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination